Next Article in Journal
Synthesis and Conformational Analysis of Naphthoxazine-Fused Phenanthrene Derivatives
Next Article in Special Issue
Synthesis, Molecular Recognition Study and Liquid Membrane-Based Applications of Highly Lipophilic Enantiopure Acridino-Crown Ethers
Previous Article in Journal
Functional Expression and Characterization of a Panel of Cobalt and Iron-Dependent Nitrile Hydratases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 11
10.3390/molecules25112523
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Discovery of New Apoptosis-Inducing Agents for Breast Cancer Based on Ethyl 2-Amino-4,5,6,7-Tetra Hydrobenzo[b]Thiophene-3-Carboxylate: Synthesis, In Vitro, and In Vivo Activity Evaluation

by
Emad M. Gad
1,*,
Mohamed S. Nafie
1,
Elsayed H. Eltamany
1,
Magdy S. A. G. Hammad
1,
Assem Barakat
2,3 and
Ahmed T. A. Boraei
1,*
1
Chemistry Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt
2
Chemistry Department, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
3
Chemistry Department, Faculty of Science, Alexandria University, P.O. Box 426, Ibrahimia, Alexandria 21321, Egypt
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(11), 2523; https://doi.org/10.3390/molecules25112523
Submission received: 26 April 2020 / Revised: 17 May 2020 / Accepted: 25 May 2020 / Published: 28 May 2020
(This article belongs to the Special Issue Nitrogen-Containing Heterocycles as Significant Molecular Scaffolds for Medicinal and Other Applications)
Browse Figures
Versions Notes

Abstract

:
A multicomponent synthesis was empolyed for the synthesis of ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 1. An interesting cyclization was obtained when the amino-ester 1 reacted with ethyl isothiocyanate to give the benzo[4,5]thieno[2,3-d][1,3]thiazin-4-one 3. Acylation of the amino-ester 1 with chloroacetyl chloride in DCM and Et3N afforded the acylated ester 4. The amino-ester 1 was cyclized to benzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one 8, which was reacted with some alkylating agents leading to alkylation at nitrogen 9–13. Hydrazide 14 was utilized as a synthon for the synthesis of the derivatives 15–19. Chloro-thieno[2,3-d]pyrimidine 20 was synthesized and reacted with the hydrazine hydrate to afford the hydrazino derivative 21, which was used as a scaffold for getting the derivatives 22–28. Nucleophilic substitution reactions were used for getting the compounds 29–35 from chloro-thieno[2,3-d]pyrimidine 20. In the way of anticancer therapeutics development, the requisite compounds were assessed for their cytotoxicity in vitro against MCF-7 and HepG-2 cancer cell lines. Twelve compounds showed an interesting antiproliferative potential with IC50 from 23.2 to 95.9 µM. The flow cytometric analysis results showed that hit 4 induces the apoptosis in MCF-7 cells with a significant 26.86% reduction in cell viability. The in vivo study revealed a significant decrease in the solid tumor mass (26.6%) upon treatment with compound 4. Moreover, in silico study as an agonist for inhibitors of JAK2 and prediction study determined their binding energies and predicted their physicochemical properties and drug-likeness scores.

Graphical Abstract

1. Introduction

The development and discovery of high efficacy anticancer agents by many molecular oriented strategies and techniques have increased in the last decades [1]. Globcan in 2018 provided a statistical report worldwide on the global burden of cancer, which shows 18.1 million new cancer incidences and 9.6 million mortalities. The female breast cancer is the second type of cancer, leading to death with 11.6%. The statics show that in every 8–10 women, one gets developed with breast cancer. Moreover, the fourth fatal cancer mortality is liver cancer with 8.2% [2].
There are several reasons for the tremendous growth of cancer mortality and new cases worldwide due to an increasing number of the population, high rate of aging, as well as prevalence changes and distribution of the risk factor for cancer linked with socioeconomic development. More specifically, the risk factors responsible for the development of breast cancer are reproductive factors (e.g., late menopause, multiparty, premature menarche, do not breastfeed), genetic factors (if her mother has breast cancer), lifestyle and dietary related factors (e.g., obesity, drinking, and smoking), and environmental factors (exogenous estrogen exposure for a long time). There are several types of breast cancer treatments including chemotherapy, radiotherapy, surgery, immune, and hormone therapy but still these treatments have diverse side effects. The urgent need to discover and develop a high efficacy anticancer therapy is highly challenged. Several therapeutic potentials have been discovered for cancer treatment with different targets; one of the most promising targets for cancer therapies is the JAK family [3]. JAK family members (JAK1, JAK2, JAK3, and TYK2) play an important role in the pathogenesis of many immunological disorders and cellular malignancies. The activity of JAK kinase was described in a series of abnormal cell proliferation of the hematologic neoplasias, including B-cell non-Hodgkin’s and Hodgkin’s lymphomas, myeloid leukemias, and lymphoid [4]. One of the most molecular targets and techniques for antiproliferative and pro-apoptotic effects are to design potential JAK inhibitors.
Fused heterocycles, based on pyrimidine scaffolds, have gained significant attention due to a wide range of pharmacological applications [5]. Especially, thienopyrimidines have been discovered as anticancer agents [6,7], EGFR kinase inhibitors (compound I, IC50 = 2.6 [8]; compound II, IC50 = 0.008, and compound III, IC50 = 0.007 µM, respectively) [9], compound IV selective against HepG-2 (IC50 = 14.9 µM) [10], compound V selective against the MCF-7 breast cancer line (IC50 = 0.10 µM) [11], and tyrosine kinase inhibitors (compound VI) [12]. TargeGen, Inc. et al. have been designed as an JAK2 inhibitor based on the core structure of anilinopyrimidine, and the cell proliferation assay has shown the EC50 = 3 nM in a JAK2 V617F (compound VI) [13]. The benzo[b]-thiophene scaffold plays a crucial rule for many STAT3 inhibitors [14,15]. Additionally, the substituted cycloalkyl[b]thiophene core structure possessed a cytotoxic activity [16], also exhibited biological activities such as the AChE inhibitor [17], I3-AG85 inhibitor (compound VIII) [18], as well as the HCV replication inhibitor (compound IX, Figure 1) [19], antiviral [20], anti-inflammatory [21,22], antibacterial [23,24], and antitumor activities [25,26,27,28,29]. In the proceeding text, we have synthesized a set of compounds based on the cycloalkyl[b]thiophene with different hybrids tethered pharmacophoric/functional groups diversity (Figure 1). The target hybrids were examined against two cancer cell lines (breast cancer MCF-7 and liver cancer HepG-2), followed by an in vivo study along with the flow cytometric analysis for the most active member were also carried out. Finally, an in silico molecular docking study such as the JAK2 inhibitor determined their binding energies and predicted their physicochemical properties and drug-likeness scores.

2. Results and Discussion

2.1. Chemistry

2.1.1. Synthesis

The benzo[b]thiophene analogue 1 was synthesized in high yield using the multicomponent strategy from ethyl cyanoacetate, cyclohexanone, sulfur and triethylamine in ethanol. The amino-ester 1 was reacted with phenyl isothiocyanate in ethanol containing Et3N to afford the N,N-disubstituted thiourea derivative 2. Whereas, when it was reacted with ethyl isothiocyanate under the same conditions, surprisingly it afforded the 2-(ethylamino)-5,6,7,8-tetrahydro-4H-benzo[4,5]thieno[2,3-d][1,3]thiazin-4-one 3 (Scheme 1).
Acylation of the amino-ester 1 with chloroacetyl chloride in DCM and Et3N afforded the acylated ester 4. Compound 4 was used for the alkylation of cyclohexylamine to afford the alkylated product 5. The benzoylation of the benzo[b]thiophene analogue 1 was done by a reaction with benzoyl chloride in benzene containing triethylamine to afford the amide 6. The reaction of 1 with benzene sulfonyl chloride in ethanol yielded the sulfonamide 7 (Scheme 2).
Cyclization of the amino-ester 1 was done by reflux with formamide for 3 h to give tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one 8. Michael additions of pyrimidinone 8 to acrylonitrile as the Michael acceptor in ethanol containing Et3N led to an addition at nitrogen to give the Michael adduct 9. Alkylation of 8 with benzyl bromide, phenacyl bromide, 4-methoxyphenacyl bromide, and ethyl chloroacetate in DMF and K2CO3, afforded the N-alkylated products 10–13, respectively (Scheme 3).
Hydrazinolysis of the ester 13 to hydrazide 14 was done by a reaction with hydrazine hydrate in ethanol. The heating hydrazide 14 with phenyl isothiocyanate in dioxane for 6 h gives the phenyl thiosemicarbazide product 15. The hydrazide 14 was refluxed with benzaldehyde and acetophenone in ethanol to give the hydrazones 16 and 17, respectively. Linking the 4-amino-1,2,4-triazolethione moiety to the benzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one system separated by a methylene spacer was achieved by a reaction with CS2/aq. KOH/EtOH, to give potassium dithiocarbazate 18, which was cyclized by a reaction with hydrazine hydrate and acidification to give 19 (Scheme 4).
The chlorination of 8 was achieved by reflux in POCl3 to yield the chloro derivative 20. A reaction of 20 with NH2NH2 in ethanol formed the hydrazino compound 21. The benzoylation of 21 with benzoyl chloride provided the N-benzoyl derivative 22, while the condensation of 21 with benzaldehyde and acetophenone afforded compounds 23 and 24, respectively (Scheme 5).
Cyclization of the hydrazino derivative 21 to triazolo-pyrimidines 25 and 26 was done by reflux in acetic and formic acids, respectively. The condensation of 21 with acetyl acetone in ethanol yielded the pyrazolo derivative 27. A reaction of 21 with carbon disulfide or phenyl isothiocyanate led to cyclization to the triazolo-pyrimidine-thione 28 (Scheme 6).
Oxygen nucleophiles such as sodium methoxide and sodium ethoxide were used to substitute the chloride of 20 to afford the ethers 29 and 30, respectively. A reaction of the chloro derivative 20 with nitrogen nucleophiles such as p-toluidine, benzyl amine, 4-aminobenzoic acid, and 4-acetylaniline afforded the substituted products 31–34, respectively. The reaction of the chloro derivative 20 with 2-aminobenzoic acid afforded the pyrimido-quinazolinone 35 (Scheme 7).

2.1.2. Structural Characterization

The 1H NMR of 1 displayed the amino group as an exchangeable signal at δ 7.15 ppm. The ethoxy group protons (CH3CH2O) appeared at δ 4.15 and 1.25 ppm. 13C NMR showed the ester group carbons at δ 165.53 (C=O), 59.03 (OCH2), and 14.79 ppm for CH3. The structure of 2 showed the two exchangeable signals at δ 11.78 and 10.88 ppm. The thiocarbonyl and carbonyl groups were detected at δ 176.36 and 166.02 ppm, respectively. Compound 3 missed the ester group signals and showed only the NH signal at δ 13.43 ppm in addition to the ethyl group signals at 4.40 and 1.20 ppm. The ethyl group carbon signals were found at δ 41.08 and 12.26 ppm, which strongly recommend the cyclic structure of 3. The acetamido group signals in 4 were found at 11.66 ppm for NH and 4.57 ppm for CH2Cl. The two carbonyl groups were identified at δ 165.45 and 164.23 ppm. The benzamide 6 and sulfonamide 7 NMR showed the NH signals at δ 12.03 and 10.36 ppm, respectively. Due to cyclization, the structure of 8 showed the NH as an exchangeable signal at 12.20 ppm and pyrimidine CH at δ 7.96 ppm. The carbonyl group was identified at δ 162.89 ppm. The aza-Michael addition and nitrogen alkylation of 8 to produce 9–13 were deduced from the missing NH signal and illustrated the methylene carbon signals directly attached to the ring nitrogen (NCH2) at δ 41.84, 48.83, 52.05, 51.64, and 47.25 ppm, respectively. The NMR of hydride 14 showed the -CO-NHNH2 group as two exchangeable signals at δ 9.36 and 4.25 ppm, whereas the carbonyl carbon was identified at δ 166.55 ppm. The thiosemicarbazide 15 displayed three NH signals at δ 10.56, 9.77, and 9.33 ppm. The thiocarbonyl and carbonyl carbons were detected at δ 181.06, 167.10, and 162.50 ppm. Hydrazones 16 and 17 were confirmed from the disappearance of the NH2 signal and the detection of benzylidene CH signals around 8.30 ppm. Compound 19 displayed the NH of the ring at δ 13.54 ppm and the NH2 protons at 5.61 ppm. The C=S was found at δ 167.32 ppm. The structure of 20 missed the NH signal, while 21 illustrated the NHNH2 exchangeable signals at δ 7.81 and 4.55 ppm. The benzoylated product 22 showed two NH signals at δ 9.64 and 8.29 ppm. The hydrazones 23 and 24 displayed the NH signal at δ 11.79 and 11.49 ppm, respectively, while the benzylidene CH was observed at 7.80 ppm in the case of 23. The cyclic structures 25 and 26 did not show any NH signal; only CH signals appeared in the aromatic region at 9.48 ppm in the case of 25 and two of the CH signals at 9.55 and 8.60 ppm in the case of 26. The pyrazole ring structure 27 revealed two CH protons at δ 8.97 and 6.17 ppm for the pyrimidine and pyrazole CH. The triazole-thione moiety construction in the case of 28 was identified from the detection of an NH at δ 14.62 ppm and the thiocarbonyl carbon at 160.56 ppm. The ethers 29 and 30 showed the CH signal of the pyrimidine ring at δ 8.55 and 8.52 ppm in addition to the alkoxy group indicating signals. The NH signals appeared in the spectra of 31–34 at δ 8.34, 8.13, 5.09, and 8.49 ppm, respectively. The five-ring fused system 35 displayed the pyrimidine CH at δ 9.34 ppm, and the four phenyl protons appeared between δ 8.35 and 7.57 ppm.

2.2. Biological Activity

2.2.1. Antitumor Activity Evaluation

The synthesized compounds were tested for their antiproliferative activity against MCF-7 and HepG-2 cancer cell lines. Twelve compounds displayed a significant activity, which ranged from 23.2 to 95.9 μM. Compounds 4, 24, 29, 30, and 31 were the most active with an IC50 range from 23.2 to 49.9 μM. Compounds 5, 15, 21, 26, 27, 28, and 33 revealed a moderate activity in the range from 52.9 to 95.9 μM. The remaining derivatives showed a lower activity (Table 1).

2.2.2. Flow Cytometric Analysis

To demonstrate the apoptotic mechanistic mode of action, the MCF-7 cell line was treated with compound 4 (IC50 = 23.2 µM, 48 h incubation) compared to untreated cells as the control, which include flow cytometric analyses including an FITC/Annexin-V-FITC/PI differential apoptosis/necrosis assessment, DNA content-flow cytometry aided cell cycle analysis, and acridine orange quantitative autophagy assessment. All flow cytometric methodologies were performed according to the standard protocols, as previously described by Kattan et al., 2020 [30].

FITC/Annexin-V-FITC/PI Differential Apoptosis/Necrosis Assessment

Double-staining with annexin-FITC and propidium iodide (PI) on MCF-7 cells treated with compound 4 (IC50 = 23.2 µM), and nontreated cells served as the negative control for 48 h to investigate whether it has an induction of apoptosis and/or cell cycle progression. As displayed in Figure 2, results show that the treatment caused apoptosis in MCF-7 cells with a substantial cell viability reduction of 26.86%. The percentage of cells sub-populating in early apoptosis (AV+/PI−) was 8.73, which is 2.3 times more relative to the untreated regulation. In addition, the average late apoptotic sub-population (AV+/PI+) count was 18.13%, which is 6.6 times higher than the untreated control. Moreover, the tested compound 4 induced an increase with 1.89-fold (6.29%, compared to 3.33% for control) in cell death via necrosis, as shown in Figure 2. The results proved that the tested compound 4 effectively induced apoptosis and necrosis in MCF-7 cells.

DNA Content-Flow Cytometry Aided Cell Cycle Analysis

Cell cycle analysis is an important test that demonstrates the cell proliferation percentage during cell growth in every phase following cytotoxic compound treatment. Therefore, to analyze the cell cycle kinetics of MCF-7 cells treated with compound 4 (IC50 = 23.2 μM, 48h incubation), DNA flow cytometry was carried out to indicate phase interference with the cell cycle of the compound’s. As shown in (Figure 3), results showed an induction an increase at G2/M-phase cell-cycle arrest with 1.48-fold (25.56%, compared to 17.23% for control), and at S-phase cell-cycle arrest with 1.39-fold (23.38%, compared to 16.76% for control) in cell population distribution, this may have resulted in genetic material degradation due to the apoptosis induction indicating compound 4 antiproliferative.

Acridine Orange Quantitative Autophagy Assessment

Herein, we further investigated the effect of compound 4 (IC50 = 23.2 μM) on the autophagy process within MCF-7 using the acridine orange lysosomal stain coupled with the flow cytometric analysis. The tested compound 4 did not induce any significant cell death by autophagy, it inhibited autophagic cell death (9.59%, compared to 11.24% for control) and this proves the antiproliferative activity of compound 4 through apoptosis and necrosis as a dual activity (Figure 4).

2.2.3. In Silico Molecular Docking Studies

A molecular docking study was made to investigate the binding interactions of hit 4 towards three proteins as JAK2 inhibitors; 3ZMM, 4C62, and 5AEP whose crystal structures complexed with their co-crystallized ligands were easily accessible from the Protein Data Bank. The co-crystallized ligands of the studied proteins form hydrogen bonds with Leu 932 as the key amino acid for interaction.
As seen in (Table 2) with 3D images, compound 4 was docked inside the protein active site of the studied proteins and formed one hydrogen bond with bond length (Aº) through the carbonyl group oxygen as a hydrogen bond acceptor with the key amino acid Leu 932 as their co-crystallized ligand with binding energy −14.32, −13.39, and −11.38 Kcal/mol, respectively. Additionally, compound 4 formed lipophilic interactions with the nonpolar amino acids (Leu 155, Val 24, Ile 140, Leu 90, and Leu 141) inside the receptor pocket. Different models obtained from the docking studies indicated that the designed target 4 showed promising binding activity as JAK2 inhibitors, and this may be the proposed mode of action for the anti-breast cancer activity.

2.2.4. Bioinformatics Study

Compounds with high binding affinity through ligand-receptor interactions and binding energy towards the investigated target (Jak2/STAT3) were subjected to bioinformatics study to predict the ADME pharmacokinetics properties. Drugs consistent with Lipinski’s "five rule" (Ro5) are considered prospective in future [31,32,33,34]. For drug absorption through the intestine, TPSA surface topological polar area values should be 140, and the barrier to blood brain should be as low as 90 Å2 [30,31] The investigated compounds had good well-permeability and absorption. As shown in (Table 3) and (Figure 5), compounds had 0-1 Hydrogen-bond donor and 3-4 Hydrogen-bond acceptors. In addition, the tested compounds had log P range from 2.82 to 4.80, so they had strong toleration by cell membranes. For managing conformational changes and for oral bioavailability, the number of rotabile bond (nrotb) should be less than 10 [31,35,36]. All the investigated compounds had 1–5 nrotb. Regarding to drug-likeness scores, compounds with positive values should be considered like drugs; all the tested compounds showed 0.15–0.73 (positive values), so they seem to be drug-like.

2.2.5. In Vivo Study

Solid Ehrlich Carcinoma (SEC) was treated daily with compound 4 to evaluate the in vivo effect on tumor cell growth, beginning on day 7 following inoculation of tumor cells. The compound had a total of seven doses, starting on day 7. At the end of the procedure, the weight of the solid tumor mass was measured. There was an increase in the solid tumor mass in SEC-bearing mice. During the experimental duration, an increase in the solid tumor weight of around 155 mg was observed via the tumor development. The antitumor effect of compound 4 and 5-FU was elucidated; there was a significant decrease in the solid tumor mass by 54% (70 mg) and 67% (50 mg), respectively (Figure 6).
Accordingly, treatments with compound 4 significantly inhibited the percentage of tumor by 26.6% (tumor volume = 22 mm3) compared to the 5-FU treatment 33.3% (tumor volume = 20 mm3). The achieved results indicate that compound 4 has a promising therapeutic potential as an antitumor agent.
At the end of the experiment, animals from different groups were anesthetized, and blood samples were collected for the determination of liver enzymes ALT, AST levels, and CBC parameters, including Hb content, RBCs and WBCs counts. As seen in Table 4, in SEC-bearing mice, liver enzymes ALT and AST were found to be significantly increased to 84.65 and 97.64 (U/L), respectively, as compared to normal mice, this could be contributed to the hepatocellular damage following tumor inoculation. The treatment with compound 4, such as 5-FU, substantially reduced liver enzyme, where elevated transaminases ALT were restored to 64.28, AST to 69.89 close to the normal values measured in normal mice (43.53 and 45.75, respectively), indicating a noticeable improvement in the hepatocellular toxicity induced by SEC proliferation.
Regarding hematological parameters in SEC-bearing mice, all CBC parameters were changed upon treatment with compound 4 where the Hb content and RBCs were significantly decreased to be 3.99 (g/dL) and 3.28 (106/µL), respectively, while the WBCs count was significantly increased to be 4.89 (103/µL) compared to the normal control levels. Myelosuppression and anemia are the main issues of cancer chemotherapy. Anemia in a tumor-bearing mouse is primarily due to reductions in the RBC count and hemoglobin, which are either hemolytic or myelopathic [30]. CBC parameters for hemoglobin, RBC, and WBC levels have been greatly improved by compound 4 treatments. CBC parameters improved to 5.99, 4.43, and 4.21, respectively, relative to normal control values 7.9, 5.14, and 3.69, hence demonstrating the ability of the tested compound to cure the change of the hematological parameters.

3. Materials and Methods

All general information about the equipment used in this text, biological activities assays (in vitro MTT assay, flow cytometric analysis, in silico molecular docking, bioinformatics study, and in vivo SEC model) of full protocols have been amended in the Supplementary Materials.

3.1. Synthesis

Synthesis of (1): Sulpher (0.02 mol) was added to a mixture of ethyl cyanoacetate (0.03 mol) and cyclohexanone (0.03 mol) in 30 mL of ethanol followed by the addition of Et3N (4.3 mmol), the mixture kept on stirring at an ambient temperature for 2 h, then refluxed for further 2 h. The reaction progress was monitored by TLC then, cooled, added to ice water, and kept overnight to complete the precipitation. The ppt was filtered, washed with water, dried, and recrystallized from ethanol to give yellow needle crystals.
Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (1)
Yield: 86%, m.p. 110–111 °C; 1H NMR (400 MHZ, DMSO-d6): δ 7.15 (s, 2H, D2O exchangeable, NH2), 4.15 (q, 2H, OCH2CH3), 2.42, 2.61 (2 m, 4H, 2 CH2cyhex), 1.67–1.69 (m, 4H, 2 CH2cyhex), 1.25 (t, 3H, J 6.0 Hz, CH3); 13C NMR (100 MHZ, DMSO-d6): δ 165.53, 163.33, 131.80, 115.97, 103.25 (4 Cthiophene, C=O), 59.03 (OCH2), 26.98, 24.41, 23.31, 22.19 (4 CH2cyhex), 14.79 (CH3); CHN calcd. for: C11H15NO2S [225.08]: C, 58.64; H, 6.71; N, 6.22; S, 14.23; found: C, 58.54; H, 6.69; N, 6.26; S, 14.12.
Synthesis of (2) and (3): A mixture of amino-ester 1 (2.2 mmol) and the appropriate isothiocyanate (2.2 mmol) and Et3N 0.5 mL was refluxed in 30 mL of absolute ethanol for 3 h then left to cool. Acidified with concentrated HCl, the formed ppt was collected by filtrations, washed with water, dried, and recrystallized from ethanol.
Ethyl 2-(3-phenylthioureido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (2)
Yield: 73%, m.p. 173–174 °C; 1H NMR (400 MHz, DMSO-d6): δ 11.78 (s, 1H, D2O exchangeable, NH), 10.88 (s, 1H, D2O exchangeable, NHPh), 7.49 (d, 2H, Ph), 7.41 (t, 2H, Ph), 7.24 (t, 1H, Ph), 4.23 (q, 2H, OCH2CH3), 2.72 (s, 2H, CH2cyhex), 2.60 (s, 2H, 2 CH2cyhex), 1.73 (s, 4H, 2 CH2cyhex), 1.28 (t, 3H, OCH2CH3); 13C NMR (100 MHz, DMSO-d6): δ 176.36 (C=S), 166.02 (C=O), 150.00, 138.69, 130.49, 129.35, 126.34, 126.14, 124.78, 112.42, (4 Cthiophene, 6 Cphenyl), 60.72 (OCH2CH3), 26.34, 24.12, 23.01, 22.91, (4 CH2cyhex), 14.52 (CH2CH3); CHN calcd. for: C18H20N2O2S2 [360.49]: C, 59.97; H, 5.59; N, 7.77; S, 17.79; found: C, 59.95; H, 5.56; N, 7.73; S, 17.77.
2-(Ethylamino)-5,6,7,8-tetrahydro-4H-benzo[4,5]thieno[2,3-d][1,3]thiazin-4-one (3)
Yield: 70%, m.p. 265–267 °C; 1H NMR (400 MHz, DMSO-d6): δ 13.43 (s, 1H, D2O exchangeable, NH), 4.40 (q, 2H, NHCH2CH3), 2.78, 2.64 (2brs, 4H, 2 CH2cyhex), 1.75 (m, 4H, 2 CH2cyhex), 1.20 (t, 3H, CH2CH3 ); 13C NMR (100 MHz, DMSO-d6): δ 173.56, 156.64 (C=O, Cthiazin), 149.02, 131.38, 128.77, 116.17 (4 Cthiophene), 41.08 (NHCH2CH3), 25.32, 24.40, 22.91, 22.01 (4 CH2cyhex), 12.26 (CH2CH3); CHN calcd. for: C12H14N2OS2 [266.38]: C, 54.11; H, 5.30; N, 10.52; S, 24.07; found: C, 54.22; H, 5.32; N, 10.50; S, 24.04.
Acylation with Chloroacetyl Chloride: A mixture of 1 (4.5 mmol) and chloroacetyl chloride (13.5 mmol) in 30 mL of methylene chloride containing Et3N (0.5 mL) was stirred for 3 h in an ice bath. The formed solid product was collected by filtration, dried, and recrystallized from ethanol.
Ethyl 2-(2-chloroacetamido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (4)
Yield: 75%, m.p. 110–112 °C; 1H NMR (400 MHz, DMSO-d6):δ 11.66 (s, 1H, D2O exchangeable, NH), 4.57 (s, 2H, CH2Cl), 4.32 (q, 2H, OCH2CH3), 2.71 (s, 4H, 2 CH2cyhex), 2.61 (s, 2H, 2 CH2cyhex), 1.73 (s, 4H, 2 CH2cyhex), 1.32 (t, 3H, CH2CH3); 13C NMR (100 MHz, DMSO-d6): δ 165.45, 164.23 (C=Oamide+ester), 145.55, 131.18, 127.30, 112.78 (4 Cthiophene), 61.00 (OCH2CH3), 43.01 (CH2Cl), 26.24, 24.20, 22.89, 22.70 (4 CH2cyhex), 14.52 (CH2CH3); CHN calcd. for: C13H16ClNO3S [301.79]: C, 51.74; H, 5.34; N, 4.64; S, 10.62; found: C, 51.76; H, 5.30; N, 4.62; S, 10.63.
Synthesis of (5): A mixture of 4 (1.6 mmol) and cyclohexylamine (1.6 mmol) was refluxed in 30 mL of absolute ethanol for 3 h and cooled to room temperature. The formed solid was filtered, dried, and recrystallized from ethanol.
Ethyl 2-(2-(cyclohexylamino)acetamido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (5)
Yield: 69%, m.p. 140–141 °C; 1H NMR (400 MHz, DMSO-d6): δ 1.29–4.69 (m, 28H); 13C NMR (100 MHz, DMSO-d6): δ 171.22, 164.75 (2 C=Oamide+ester), 146.07, 131.04, 126.12, 111.77 (4 Cthiophene,), 60.46 (OCH2CH3), 57.35, 49.99, 33.25, 26.33, 26.17, 24.89, 24.26, 23.01, 22.85 (9 CH2cyhex, CHcyhex), 14.67 (CH2CH3); CHN calcd. for: C19H28N2O3S [364.50]: C, 62.61; H, 7.74; N, 7.69; S, 8.80; found: C, 62.60; H, 7.70; N, 7.66; S, 8.81.
Synthesis of (6): A mixture of 1 (3.8 mmol), benzoyl chloride (4.3 mmol), and few drops of triethylamine was refluxed for 4 h in dry benzene. The reaction mixture was concentrated and cooled at room temperature. The formed ppt was collected and recrystallized from ethanol to obtain yellow crystals.
Ethyl 2-benzamido-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (6)
Yield: 8%, m.p. 170–172 °C; 1H NMR (400 MHz, DMSO-d6): δ 12.03 (s, 1H, D2O exchangeable, NH), 7.64–7.93 (m, 5H, phenyl), 4.35 (q, 2H, OCH2CH3), 2.66, 2.76 (2brs, 4H, 2 CH2cyhex), 1.76 (brs, 4H, 2 CH2cyhex), 1.35 (t, 3H, CH2CH3); 13C NMR (100 MHz, DMSO-d6): δ 166.23, 163.06 (2 C=Oester+amide), 147.01, 133.21, 132.54, 131.21, 129.64, 127.46, 127.03 (4 Cthiophene, 6 Cphenyl), 61.04 (OCH2CH3), 26.29, 24.27, 22.97, 22.75 (4 CH2cyhex), 14.52 (OCH2CH3); CHN calcd. for: C18H19NO3S [329.41]: C, 65.63; H, 5.81; N, 4.25; S, 9.73; found: C, 65.60; H, 5.84; N, 4.15; S, 9.5.
Synthesis of (7): A mixture of compound 1 (2.2 mmol) and benzenesulfonyl chloride (2.2 mmol) was refluxed in 30 mL of absolute ethanol for 4 h then cooled to room temperature. The ppt was collected by filtration, washed with ethanol, and recrystallized from ethanol.
Ethyl 2-(phenylsulfonamido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (7)
Yield: 73%, m.p. 107–108 °C; 1H NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1H, NH), 7.81 (d, 2H, Ph), 7.68 (t, 1H, Ph), 7.60 (t, 2H, Ph), 4.14 (q, 2H, OCH2CH3), 2.56–2.59 (m, 4H, 2 CH2cyhex), 1.68–1.69 (m, 4H, 2 CH2cyhex), 1.21 (t, 3H, OCH2CH3); 13C NMR (100 MHz, DMSO-d6): δ 163.84 (C=Oester), 142.70, 139.46, 133.87, 132.91, 130.13, 129.82, 127.29, 120.47 (4 Cthiophene+, 6 Cphenyl), 60.76 (OCH2CH3), 25.92, 24.47, 22.81, 22.42 (4 CH2cyhex), 14.38 (OCH2CH3); CHN calcd. for: C17H19NO4S2 [365.46]: C, 55.87; H, 5.24; N, 3.83; S, 17.54; found: C, 55.88; H, 5.26; N, 3.80; S, 17.56.
Synthesis of (8): A mixture of 1 (4.5 mmol) and formamide (0.44 mol) was refluxed for 3 h. Cooled, poured onto cold water, and left at room temperature overnight, the formed ppt was filtered off and recrystallized from methanol to give brown needle crystals.
4,5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (8)
Yield: 90%, m.p. 250–251 °C; 1H NMR (400 MHz, DMSO-d6): δ 12.20 (s, 1H, D2O exchangeable, NH), 7.96 (s, 1H, CHpyrimid.), 2.72, 2.86 (2brs, 4H, 2 CH2cyhex), 1.74–1.80 (m, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 162.89, 158.1, 145.2, 132.57, 131.3, 123.2 (4 Cthiophene, 2 Cpyrimidone), 25.79, 24.90, 22.94, 22.24 (4 CH2cyhex); CHN calcd. for: C10H10N2OS [206.26]: C, 58.23; H, 4.89; N, 13.58; S, 15.54; found: C, 58.25; H, 4.90; N, 13.57; S, 15.50.
Michael Addition Procedures: A mixture of pyrimidinone 8 (3.4 mmol), acrylonitrile (4.6 mmol), and Et3N (0.3 mL) in 25 mL of ethanol was refluxed for 6 h, left to cool, a solid product formed, filtered off, and recrystallized from ethanol to give colorless crystals.
3-(4-Oxo-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)propanenitrile (9)
Yield: 73%, m.p. 173–175 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.37 (s, 1H, CHpyrimidine), 4.23–4.25 (m, 2H, NCH2), 3.02–3.04 (m, 2H, CH2CH2CN), 2.89 (brs, 2H, CH2cyhex), 2.75 (brs, 2H, CH2cyhex), 1.79 (brs, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 162.10 (C=O pyrimidone), 157.20, 147.55, 133.79, 131.35, 122.15, 118.56 (6 C(1pyrimidone+4thiophene+CN)), 41.84 (NCH2), 25.77, 25.02, 22.85, 22.20 (4 CH2cyhex), 17.49 (CH2CN); CHN calcd. for: C13H13N3OS [259.33]: C, 60.21; H, 5.05; N, 16.20; S, 12.36; found: C, 60.23; H, 5.10; N, 16.23; S, 12.34.
General Procedure for Preparation of Compounds (10–13): To a mixture of pyrimidinone 8 (3.0 mmol), the appropriate alkyl halide (3.3 mmol) and anhydrous potassium carbonate (3.6 mmol) was refluxed in 20 mL of DMF for 4 h. Then cooled, poured in cold water, the ppt was filtered off and recrystallized from ethanol to afford the alkylated products 10–13.
3-Benzyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (10)
Yield: 73%, m.p. 190 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.47 (s, 1H, CHpyrimidine), 7.34 (s, 5 Hphenyl), 5.18 (s, 2H, NCH2), 2.90–2.89 (m, 2H, CH2cyhex), 2.75–2.74 (m, 2H, CH2cyhex), 1.81–1.75 (m, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 162.01 (C=Opyrimidone), 157.32, 147.92, 137.36, 133.62, 131.38, 129.07, 128.09, 122.42 (11 C(1pyrimidone+4thiophene+6phenyl)), 48.83 (NCH2), 25.81, 25.01, 22.84, 22.21 (4 CH2cyhex); CHN calcd. for: C17H16N2OS [296.39]: C, 68.89; H, 5.44; N, 9.45; S, 10.82; found: C, 68.88; H, 5.46; N, 9.43; S, 10.80.
3-(2-Oxo-2-phenylethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (11)
Yield: 85% pale brown crystals, m.p. 190–192 °C; 1H NMR (400 MHz, DMSO-d6 ): δ 8.29 (s, 1H, CHpyrimidine), 8.10 (d, 2 Hphenyl), 7.75 (t, 2 Hphenyl), 7.62 (t, 1 Hphenyl), 5.60 (s, 2H, NCH2), 2.86 (brs, 2H, CH2cyhex), 2.78 (brs, 2H, CH2cyhex), 1.78–1.83 (m, 4H, 2CH2cyhex); 13C NMR (100 MHz, DMSO-d6 ): δ 193.25 (C=Ophenacyl), 162.22 (C=Opyrimidine), 157.26, 148.28, 134.91, 134.59, 133.67, 131.33, 129.47, 128.50, 122.20 (11 C(4thiophene+ 1pyrimidine+6phenyl)), 52.05 (NCH2), 25.76, 25.03, 22.88, 22.22 (4 CH2cyhex); CHN calcd. for: C18H16N2O2S [324.40]: C, 66.64; H, 4.97; N, 8.64; S, 9.88; found: C, 66.60; H, 4.95; N, 8.66; S, 9.90.
3-(2-(4-methoxyphenyl)-2-oxoethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (12)
Yield: 90% as yellow crystals, m.p. 145–146 °C; 1H NMR (400 MHz, DMSO-d6 ): δ 8.27 (s, 1H, CHpyrimidine), 8.08 (d, 2 Hphenyl), 7.14 (d, 2 Hphenyl), 5.53 (s, 2H, NCH2), 3.90 (s, 3H, OCH3 ), 2.86 (s, 2H, CH2cyhex), 2.78 (s, 2H, CH2cyhex), 1.77–1.81 (m, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 191.48 (C=Ophenacyl), 164.35 (C=Opyrimidine), 162.24, 157.29, 148.36, 133.58, 131.32, 130.88, 127.81, 122.20, 114.72 (11 C(4thiophene+ 1pyrimidine+6phenyl)), 56.14 (OCH3), 51.64 (NCH2), 25.76, 25.02, 22.88, 22.22 (4 CH2cyhex); CHN calcd. for: C19H18N2O3S [354.42]: C, 64.39; H, 5.12; N, 7.90; S, 9.05; found: C, 64.41; H, 5.14; N, 7.93; S, 9.00.
Ethyl 2-(4-oxo-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)acetate (13)
Yield: 82% pale brown needles, m.p. 113–114 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.30 (s, 1H, CHpyrimdine), 4.79 (s, 2H, NCH2), 4.18 (q, J=8.0 Hz, 2H, OCH2CH3), 2.87 (brs, 2H, CH2cyhex), 2.65 (brs, 2H, CH2cyhex), 1.79 (m, 4H, 2CH2cyhex), 1.23 (t, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): δ 168.29 (C=Oester), 162.17 (C=Opyrimidine), 157.21, 147.95, 133.85, 131.29, 122.08 (4 Cthiophene, 1 Cpyrimidine), 61.71 (OCH2CH3), 47.25 (NCH2), 25.72, 25.00, 22.85, 22.19 (4 CH2cyhex), 14.45 (CH2CH3); CHN calcd. for: C14H16N2O3S [292.35]: C, 57.52; H, 5.52; N, 9.58; S, 10.97; found: C, 57.48; H, 5.50; N, 9.61; S, 10.99.
Synthesis of (14): A mixture of ester 13 (3.0 mmol) and hydrazine hydrate (6.0 mmol) in 30 mL of ethanol was refluxed for 3 h, the reaction mixture was cooled, the solid product was filtered off, dried, and recrystallized from EtOH/DMF.
2-(4-Oxo-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)acetohydrazide (14)
Yield: 91% as white crystals, m.p. 246–248 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.36 (s, 1H, D2O exchangeable, NH), 8.22 (s, 1H, CHpyrimdine), 4.58 (s, 2H, NCH2), 4.27 (s, 2H, D2O exchangeable, NH2), 2.86 (brs, 2H, CH2cyhex), 2.76 (brs, 2H, CH2cyhex), 1.77–1.80 (m, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 166.55, 162.13 (2 C=O(amide+pyrimidone)), 157.32, 148.55, 133.36, 131.28, 122.13 (5 C(1pyrimidine+4thiophene)), 46.85 (NCH2), 25.77, 25.00, 22.88, 22.24 (4 CH2cyhex); CHN calcd. for: C12H14N4O2S [278.33]: C, 51.78; H, 5.07; N, 20.13; S, 11.52; found: C, 51.80; H, 5.17; N, 20.11; S, 11.55.
Synthesis of (15): To a mixture of hydrazide 14 (3.0 mmol) in 30 mL of dioxane, phenyl isothiocyanate (3.7 mmol) was added, the reaction mixture was kept under reflux for 6 h, concentrated, cooled, and left overnight. The formed ppt was collected and recrystallized from ethanol to give 15 as white crystals.
2-(2-(4-Oxo-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)acetyl)-N-phenylhydrazine-1-carbothioamide (15)
Yield: 85%, m.p. 155–156 °C; 1H NMR (400 MHz, DMSO-d6): δ 10.56, 9.77, 9.33 (3s, 3H, D2O exchangeable, 3NH), 8.30 (s, 1H, CHpyrimidone), 7.59 (d, 2H, J 8 Hz, 2HAr), 7.35 (t, 2H, 2HAr), 7.17–7.20 (m, 1H, 1HAr ), 4.74 (s, 2H, NCH2), 2.81 (brs, 2H, CH2cyhex), 2.77 (brs, 2H, CH2cyhex), 1.74–1.80 (m, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 181.06 (C=S), 167.10, 162.5 (2 C=Opyrimidone+amide), 157.88, 148.23, 139.38, 133.91, 131.16, 128.57, 125.55, 125.21, 122.12 (11 C(1pyrimidone+4thiophene+6phenyl)), 47.98 (NCH2), 25.76, 25.01, 22.84, 22.18 (4 CH2cyhex); CHN calcd. for: C19H19N5O2S2 [413.51]: C, 55.19; H, 4.63; N, 16.94; S, 15.51; found: C, 55.23; H, 4.60; N, 16.92; S, 15.50.
General Procedures for Synthesis of Compounds (16) and (17): To a mixture of hydrazide (3.0 mmol) in 30 mL of ethanol, the selected aldehyde or ketone (3.3 mmol) was added and refluxed for 6 h. Then, concentrated and left overnight, the formed ppt was recrystallized from ethanol to give 16 and 17.
(E)-N’-Benzylidene-2-(4-oxo-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)acetohydrazide (16)
Yield: 52%, m.p. 230 °C; 1H NMR (400 MHz, DMSO-d6): δ 11.65 (s, 1H, D2O exchangeable, NH), 8.29 (s, 1H, N=CH), 8.08 (s, 1H, CHpyrimidone), 7.73–7.74 (m, 2H, Ph), 7.46 (brs, 3H, Ph), 5.20 (s, 2H, NCH2), 2.89 (brs, 2H, CH2cyhex), 2.78 (brs, 2H, CH2cyhex), 1.79–1.84 (m, 4H, 2CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 168.69, 162.16 (2 C=Oamide+pyrimidone), 157.46, 148.61, 144.78, 134.37, 133.52, 131.30, 130.55, 129.33, 127.38, 122.16 (12 C(1pyrimidone+4thiophene+ 6phenyl+N=CH)), 46.94 (NCH2), 25.78, 25.01, 22.87, 22.23 (4 CH2cyhex); CHN calcd. for: C19H18N4O2S [366.44]: C, 62.28; H, 4.95; N, 15.29; S, 8.75; found: C, 62.30; H, 4.92; N, 15.31; S, 8.73.
(E)-2-(4-Oxo-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)-N’-(1-phenylethylidene)acetohydrazide (17)
Yield: 50%, m.p. 230 °C; 1H NMR (400 MHz, DMSO-d6): δ 11.00 (s, 1H, D2O exchangeable, NH), 8.30 (s, 1H, CHpyrimidone), 7.80–7.86 (m, 2H, 2HAr), 7.43 (brs, 3H, 3HAr), 5.23 (s, 2H, NCH2), 2.88 (brs, 2H, CH2cyhex), 2.78 (brs, 2H, CH2cyhex), 2.31 (s, 3H, CH3), 1.79–1.81 (m, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 169.55, 162.19 (C=Oamide+pyrimidone), 157.50, 149.44, 148.59, 138.32, 133.56, 131.29, 129.77, 128.90, 126.83, 126.58, 122.17 (12 C(N=C+1pyrimidone+4thiophene+6phenyl)), 47.37 (NCH2), 25.77, 25.00, 22.85, 22.21 (4 CH2cyhex), 14.09 (CH3); CHN calcd. for: C20H20N4O2S [380.46]: C, 63.14; H, 5.30; N, 14.73; S, 8.43; found: C, 63.12; H, 5.33; N, 14.75; S, 8.42.
Synthesis of (19): To hydrazide 14 (3.0 mmol) in 30 mL of absolute ethanol containing aq. KOH (6.0 mmol), carbon disulphide (6.0 mmol) and the mixture was stirred at room temperature for 3 h, then the solvent was removed on a water bath to get the yellow ppt of 18, which was directly used for the next step without further purification. To potassium salt 18 (3.0 mmol) in 10 mL of water, hydrazine hydrate (6.0 mmol) was added and the mixture was refluxed for 5 h, then cooled, diluted with water, and acidified by concentrated HCl. The formed ppt was collected, dried, and recrystallized from ethanol to give white plates crystals from 19.
3-((4-Amino-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (19)
Yield: 77%, m.p. 269–271 °C; 1H NMR (400 MHz, DMSO-d6 ): δ 13.54 (s, 1H, exchangeable, NH), 8.38 (s, 1H, CHpyrimidine), 5.61 (s, 2H, D2O exchangeable, NH2), 5.25 (s, 2H, NCH2), 2.87 (t, 2H, CH2cyhex), 2.77 (t, 2H, CH2cyhex), 1.75–1.83 (m, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 167.32 (C=Sthioamide), 162.06 (C=Opyrimidone), 157.03, 148.62, 148.14, 133.80, 131.35, 122.17 (6 C(triazole+pyrimidine+4thiophene), 40.2 (NCH2), 25.75, 25.01, 22.84, 22.19 (4 CH2cyhex); CHN calcd. for: C13H14N6OS2 [334.42]: C, 46.69; H, 4.22; N, 25.13; S, 19.18; found: C, 46.66; H, 4.20; N, 25.15; S, 19.21.
Synthesis of (20): The benzothieno[2,3-d]pyrimidine 8 (4.5 mmol) was refluxed in POCl3 (20 mL) for 3 h. The mixture was cooled and added into ice/water. The formed ppt was filtered off, washed several times with water, dried, and recrystallized from EtOH to give colorless needle crystals.
4-Chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (20)
Yield: 64%, m.p. 110–112 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.78 (s, 1H, CHpyrimdine), 2.98 (s, 2H, CH2cyhex), 2.88 (s, 2H, CH2cyhex), 1.85 (s, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 158.00, 145.25, 132.65, 131.31, 123.22 (5 CCHpyrimidine+4Cthiophene)), 25.76, 24.90, 22.92, 22.22 (4 CH2cyhex); CHN calcd. for: C10H9ClN2S [224.70]: C, 53.45; H, 4.04; N, 12.47; S, 14.27; found: C, 53.47; H, 4.03; N, 12.49; S, 14.25.
Synthesis of (21): A mixture 20 (3.6 mmol) and hydrazine hydrate (0.03 mmol) in 35 mL of ethanol was refluxed for 5 h, then concentrated to half, the formed solid product was filtered off, dried, and recrystallized from ethanol.
4-Hydrazineyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (21)
Yield: 85% as pale brown crystals, m.p. 175–176 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.33 (s, 2H, CHpyrimidine), 7.81 (s, 1H, D2O exchangeable, NH), 4.55 (s, 2H, D2O exchangeable, NH2), 2.93 (brs, 2H, CH2cyhex), 2.76 (brs, 2H, CH2cyhex), 1.80 (brs, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 164.42, 158.76 (2 Cpyrimidine), 152.93, 131.97, 127.26, 115.32 (4 Cthiophene), 25.89, 25.35, 22.63, 22.50 (4 CH2cyhex); CHN calcd. for: C10H12N4S [220.29]: C, 54.52; H, 5.49; N, 25.43; S, 14.55; found: C, 54.49; H, 5.51; N, 25.44; S, 14.57.
Synthesis of (22): To hydrazide 21 (1.8 mmol) in 20 mL of absolute ethanol, benzoyl chloride (2 mmol) was added, the reaction mixture was refluxed for 6 h, then cooled. The formed solid product was filtered off and recrystallized from acetic acid.
N’-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)benzohydrazide (22)
Yield: 68% brown crystals, m.p. 198–200 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.64 (s, 1H, NH), 8.29 (s, 2H, CHpyrimdine+NH), 7.59–7.60 (m, 5H, Ar), 3.22 (brs, 2H, CH2cyhex), 2.97 (brs, 2H, CH2cyhex), 1.91–1.95 (m, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 164.38 (C=O), 153.33, 149.51, 138.69, 137.41, 131.13, 130.43, 129.44, 129.18, 127.66, 120.05 (12 C(2pyrimdine+ thiophene+phenyl)), 25.40, 23.00, 22.17, 21.44 (4 CH2cyhex); CHN calcd. for: C17H16N4OS [324.40]: C, 62.94; H, 4.97; N, 17.27; S, 9.88; found: C, 62.90; H, 4.96; N, 17.24; S, 9.85.
The General Procedure for Synthesis of Compounds (23) and (24): A mixture of 21 (1.6 mmol) and the selected aldehyde or ketone (2.0 mmol) in 20 mL of ethanol, was refluxed for 4 h, on cooling, the solid product was filtered off, dried, and recrystallized from ethanol to give compounds 23 and 24.
(E)-4-(2-benzylidenehydrazineyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (23)
Yield: 80% pale brown needles, m.p. 108–110 °C; 1H NMR (400 MHz, DMSO-d6): δ 11.79 (s, 1H, D2O exchangeable, NH), 8.40 (s, 1H, CHpyrimidine), 7.94 (brs, 2 Hphenyl), 7.80 (s, 1H, N=CH-Ph), 7.39–7.46 (m, 3 Hphenyl), 3.01 (brs, 2H, CH2cyhex), 2.76 (brs, 2H, CH2cyhex), 1.80 (brs, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 157.81, 153.32 (2 Cpyrimidine), 149.51, 144.31, 135.91, 132.78, 131.35, 130.33, 129.80, 128.55, 119.37 (11 C(4thiophene+7N=CH-C6H5)), 26.99, 25.20, 22.86, 22.52 (4 CH2cyhex); CHN calcd. for: C17H16N4S [308.40]: C, 66.21; H, 5.23; N, 18.17; S, 10.40; found: C, 66.20; H, 5.26; N, 18.20; S, 10.20.
(E)-4-(2-(1-phenylethylidene)hydrazineyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (24)
Yield: 85% red crystals, m.p. 178–180 °C; 1H NMR (400 MHz, DMSO-d6): δ 11.49 (s, 1H, D2O exchangeable, NH ), 8.02 (brs, 2 Hphenyl), 7.78 (s, 1H, CHpyrimidine), 7.41–7.43 (m, 3 Hphenyl), 3.04 (brs, 2H, CH2cyhex), 2.75 (brs, 2H, CH2cyhex), 2.45 (s, 3H, CH3), 1.81 (brs, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 157.97, 157.32, 147.94, 144.42, 139.20, 132.73, 131.34, 129.36, 128.53, 127.01, 120.14 (13 C (4thiophene+6phenyl+2pyrimidine+N=C), 26.87, 25.18, 22.88, 22.65 (4 CH2cyhex), 14.68 (CH3); CHN calcd. for: C18H18N4S [322.43]: C, 67.05; H, 5.63; N, 17.38; S, 9.94; found: C, 67.04; H, 5.66; N, 17.34; S, 9.99.
Synthesis of (25) and (26): Hydrazino derivative 21 (2.7 mmol) was refluxed in a glacial acetic acid or formic acid (3.5 mmol) for 4 h, then concentrated, cooled, and poured into cold water. The formed ppt was filtered off, washed with water, dried, and recrystallized from ethanol.
3-Methyl-8,9,10,11-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine (25)
Yield: 80%, m.p. 180 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.48 (s, 1H, CHpyrimidine), 3.05 (brs, 2H, CH2cychex), 2.91 (brs, 2H, CH2cychex), 2.56 (s, 3H, CH3), 1.90 (brs, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 164.68, 153.05, 148.96 (3 C(2pyrimidine+1triazol)), 138.35, 136.97, 128.92, 119.96 (4 Cthiophene), 25.33, 22.95, 22.15 (4 CH2cyhex), 14.64 (CH3); CHN calcd. for: C12H12N4S [344.32]: C, 58.99; H, 4.95; N, 22.93; S, 13.12; found: C, 58.98; H, 4.97; N, 22.90; S, 13.05.
8,9,10,11-Tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine (26)
Yield: 65%, m.p. 136 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.55 (s, 1H, CHpyrimdine), 8.60 (s, 1H, CHtriazole), 3.02–3.04 (m, 2H, CH2cyhex), 2.89–2.90 (m, 2H, CH2cyhex), 1.89–1.93 (m, 4H, 2 CH2cyhex); 13C NM (100 MHz, DMSO-d6): δ 155.09, 152.86, 148.26, 138.69, 137.48, 128.86, 120.14 (7 C(1triazole+2pyrimdine+4thiophene)), 25.28, 25.22, 22.89, 22.10 (4 CH2cyhex); CHN calcd. for: C11H10N4S [230.29]: C, 57.37; H, 4.38; N, 24.33; S, 13.92; found: C, 57.39; H, 4.40; N, 24.31; S, 13.90.
Synthesis of (27): A mixture of hydrazino derivative 21 (2.7 mmol) and acetyl acetone (2.8 mmol) in 20 mL abs. ethanol was refluxed for 6 h on cooling, a ppt is formed which was filtered and recrystallized from ethanol.
4-(3,5-Dimethyl-1H-pyrazol-1-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (27)
Yield: 67% yellow needles, m.p. 151–153 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.97 (s, 1H, CHpyrimidine), 6.17 (s, 1H, CHpyrazolyl), 2.92 (brs, 2H, CH2cyhex), 2.21–2.30 (m, 8H, 2 CH3+CH2cyhex), 1.83–1.84 (m, 2H, CH2cyhex), 1.66 (brs, 2H, CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 170.45, 152.00 (2 Cpyrimidine), 151.77, 149.42, 141.85, 139.55, 127.50, 126.14, 107.85 (7 C(3pyrazole+4thiophene)), 25.95, 24.91, 22.58, 22.13 (4 CH2cyhex), 13.70, 11.80 (2CH3); CHN calcd. for: C15H16N4S [284.38]: C, 63.35; H, 5.67; N, 19.70; S, 11.28; found: C, 63.38; H, 5.65; N, 19.71; S, 11.26.
Synthesis of (28)
Method A: To the hydrazino derivative 21 (2.7 mmol) in 20 mL of ethanol containing aq. KOH (6.0 mmol) carbon disulfide (3.0 mmol) was added, the reaction mixture was refluxed for 6 h, then cooled, diluted with water, and acidified with concentrated HCl. A yellow ppt is formed, filtered off, washed with water, dried, and recrystallized from ethanol to give brown crystals.
Method B: A mixture of hydrazino derivative 21 (1.8 mmol) and phenyl isothiocyanate (2.0 mmol) in 10 mL of ethanol was refluxed for 6 h. After that cooling, the solid product is formed, filtered off, and recrystallized from ethanol.
8,9,10,11-Tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine-3(2H)-thione (28)
Yield: 85A%, 65B%, m.p. 283–285 °C; 1H NMR (400 MHz, DMSO-d6): δ 14.62 (s, 1H, D2O exchangeable, NH), 8.87 (s, 1H, CHpyrimidine), 2.90 (brs, 4H, 2 CH2cyhex), 1.88 (brs, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 160.56, 151.28, 143.19 (3 C(pyrimidine+C=S thioamide)), 138.78, 135.69, 129.59, 117.23 (4 Cthiophene ), 25.14, 22.88, 22.05 (4 CH2cyhex); CHN calcd. for: C11H10N4S2 [262.35]: C, 50.36; H, 3.84; N, 21.36; S, 24.4; found: C, 50.32; H, 3.86; N, 21.32; S, 24.3.
The General Procedure for Synthesis of Compounds (29) and (30): The chloro derivative 20 (1.8 mmol) was refluxed in sodium methoxide or sodium ethoxide (prepared from 0.23 g of sodium in 30 mL of ethanol or methanol) for 6 h after finishing and the solvent was concentrated. The formed solid product was filtered off and recrystallized from the water-ethanol mixture.
4-Methoxy-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (29)
Yield: 71.8% colorless needle crystals, m.p. 98–100 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.55 (s, 1H, CHpyrimidine), 4.04 (s, 3H, OCH3), 2.86 (brs, 2H, CH2cyhex), 2.80 (brs, 2H, CH2cyhex), 1.82–1.81 (m, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 166.88, 163.91 (2 Cpyrimidine), 152.67, 135.01, 127.49, 118.56 (4 Cthiophene), 54.28 (OCH3), 25.91, 25.32, 22.83, 22.26 (4 CH2cyhex); CHN calcd. for: C11H12N2OS [220.29]: C, 59.97; H, 6.35; N, 12.60; S, 14.42; found: C, 59.99; H, 6.34; N, 12.61; S, 14.38.
4-Ethoxy-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (30)
Yield: 67% white solid, m.p. 109 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.52 (s, 1H, CHpyrimidine), 4.52 (q, 2H, CH2CH3), 2.89–2.91 (m, 2H, CH2cyhex), 2.79–2.81 (m, 2H, CH2cyhex), 1.82–185 (m, 4H, 2 CH2cyhex), 1.40 (t, 3H, CH2CH3); 13C NMR (100MHz, DMSO-d6): δ 167, 163.58 (2 Cpyrimidine), 152.70, 134.88, 127.59, 118.57 (4 Cthiophene), 62.69 (OCH2), 25.86, 25.35, 22.86, 22.32 (4 Ccyhex), 14.66 (CH2CH3); CHN calcd. for: C12H14N2OS [234.31]: C, 61.51; H, 6.02; N, 11.96; S, 13.68; found: C, 61.53; H, 6.05; N, 11.99; S, 13.66.
The General Procedure for Synthesis of Compounds (31–35): A mixture of chloro derivative 20 (2.0 mmol) and the appropriate amine (2.1 mmol) in 20 mL of ethanol was refluxed for 6 h. The solvent was concentrated and on cooling a solid product is formed which was filtered off, dried, and recrystallized from ethanol to afford the corresponding compound 31–35.
N-(p-Tolyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (31)
Yield: 71%, brown plates crystals, m.p. 140–142 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.34 (s, 1H, D2O exchangeable, NH), 7.98 (s, 1H, CHpyrimidine), 7.55 (d, J 8.0 Hz, 2H, 2HAr), 7.17 (d, J 8 Hz, 2H, 2CH, 2HAr), 3.12 (brs, 2H, CH2cyhex), 2.82 (brs, 2H, CH2cyhex), 2.30 (s, 3H, CH3), 1.86 (brs, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 166.06, 155.51 (2 Cpyrimidine), 152.55, 137.02, 133.20, 132.96, 129.29, 127.01, 122.83, 117.02 (10 C(4thiophene+6phenyl)), 25.89, 25.52, 22.61, 22.48 (4 CH2cyhex), 20.93 (CH3); CHN calcd. for: C17H17N3S [295.40]: C, 69.12; H, 5.80; N, 14.22; S, 10.85; found: C, 69.10; H, 5.81; N, 14.25; S, 10.79.
N-Benzyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (32)
Yield: 65.5%, m.p. 162–164 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.54 (d, 1H, J 8.0 Hz, phenyl), 8.43 (s, 1H, CHpyrimidine), 8.13 (s, 1H, D2O exchangeable, NH), 6.98–7.11 (m, 4H, phenyl), 3.92 (s, 2H, NHCH2Ph), 3.07–3.09 (m, 2H, CH2cyhex), 2.82–2.84 (m, 2H, CH2cyhex), 1.87–1.94 (m, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 165.60, 154.84 (2 Cpyrimidine), 152.71, 149.38, 134.05, 128.79, 126.24, 123.66, 121.03, 117.15, 111.42 (10 C(6phenyl+4thiophene)), 56.77 (CH2-NHBn), 25.94, 25.49, 22.58, 22.40 (4 CH2cyhex); CHN calcd. for: C17H17N3S [295.40]: C, 69.12; H, 5.80; N, 14.22; S, 10.85; found: C, 69.10; H, 5.81; N, 14.25; S, 10.79.
4-((5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amino)benzoic acid (33)
Yield: 88% yellow crystals, m.p. 269–271 °C; 1H NMR (400 MHz, DMSO-d6): 8.50 (s, 2H, CHpyrimidine+COOH), 7.93 (d, 2H, J 8.0 HZ, 2HAr), 7.82 (d, 2H, J 8.0 Hz, 2HAr), 5.09 (s, 1H, D2O exchangeable, NH), 3.16 (brs, 2H, CH2cyhex), 2.86 (brs, 2H, CH2cyhex), 1.92 (brs, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 167.43 (C=O), 165.69, 154.72 (2 Cpyrimidine), 151.97, 143.99, 134.49, 130.50, 127.13, 125.30, 120.89, 118.14 (10 C(4thiophene+ 6phenyl)), 25.71, 25.59, 22.60, 22.40 (4 CH2cyhex); CHN calcd. for: C17H15N3O2S [325.39]: C, 62.75; H, 4.65; N, 12.91; S, 9.85; found: C, 62.80; H, 4.60; N, 12.93; S, 9.87.
1-(4-((5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amino)phenyl)ethan-1-one (34)
Yield: 67% brown crystals, m.p. 173–175 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.49 (s, 1H, D2O exchangeable, NH), 8.38 (s, 1H, CHpyrimidine), 7.94 (d, 2H, J 8.0 Hz, 2HAr), 7.83 (d, 2H, J 8.0 Hz, 2HAr), 3.14 (brs, 2H, CH2cyhex), 2.84 (brs, 2H, CH2cyhex), 2.54 (s, 3H, OCH3), 1.87 (brs, 4H, 2 CH2cyhex); 13C NMR (100 MHz, DMSO-d6): δ 196.81 (C=O), 166.86, 154.51 (2 Cpyrimidine), 152.27, 144.48, 134.42, 131.65, 129.55, 126.94, 120.42, 118.17 (10 C(6phenyl+4thiophene)), 26.81 (CH3), 25.7, 25.59, 22.60, 22.42 (4 CH2cyhex); CHN calcd. for: C18H17N3OS [323.41]: C, 66.85; H, 5.30; N, 12.99; S, 9.91; found: C, 66.82; H, 5.31; N, 12.96; S, 9.90.
1,2,3,4-Tetrahydro-9H-benzo[4’,5’]thieno[2’,3’:4,5]pyrimido[6,1-b]quinazolin-9-one (35)
Yield: 70% yellow crystals, m.p. 285 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.34 (s, 1H, CHpyrimdine), 8.35 (d, 1 Hphenyl), 7.96 (t, 1 Hphenyl), 7.78 (d, 1 Hphenyl), 7.57 (t, 1 Hphenyl) 2.91, 1.90 (4 CH2cyhex); CHN calcd. for: C17H13N3OS [307.37]: C, 66.43; H, 4.26; N, 13.67; S, 10.43; found: C, 66.40; H, 4.24; N, 13.69; S, 10.40.

3.2. Biological Experimental Assays (Full Protocols, see Supplementary Materials)

3.2.1. In Vitro

In vitro work regarding cell culturing, cytotoxic screening using the MTT assay, and the IC50 calculations were made according to Mosmann 1983 (see Supplementary Materials) [38].

3.2.2. Flow Cytometry

All flow cytometry including FITC/Annexin-V-FITC/PI differential apoptosis/necrosis assessment, DNA content-flow cytometry aided cell cycle analysis, and acridine orange quantitative autophagy assessment were made according to Nafie et al., 2020 [39].

3.2.3. In Silico Molecular Docking

All in silico studies including ligand optimization, protein preparation, and molecular docking calculation were investigated followed by the reported [40].

3.2.4. Bioinformatics

Bioinformatics study (in silico and bioactivity prediction) of the most active compounds were calculated using a set of software’s including MolSoft, Molinspiration [41], and SwissADME [42] websites as previously described by Youssef et al., 2020 [37].

3.2.5. In Vivo (SEC) Model

Experiment design and methodology including tumor volume and percentage of tumor inhibition were summarized in Figure 7.

3.2.6. Statistical Analysis

Data were represented by the value of the mean for three different replicates, with the standard error of the mean (mean ± SEM). All statistical analysis was done as using GraphPad Prism software version 7.0. The statistical difference between two groups was examined using the unpaired t-test. The significance level was set at p < 0.05.

4. Conclusions

In conclusion, approximately 33 compounds were synthesized and characterized. The target compounds were evaluated in vitro against HepG-2 and MCF-7 cancer cell lines. Hit 4 was found to be the most active, and the cell cycle analysis showed that this lead induces apoptosis. Moreover, the in vivo study demonstrates that our target significantly reduces the tumor mass. The in silico molecular docking shows the binding of 4 as an agonist for JAK2 inhibitors.

Supplementary Materials

The following are available online, Full protocols for the biological assays; Figure S1–S87 copies of the HNMR and CNMR spectrum of the synthesized compounds.

Author Contributions

Conceptualization, E.H.E., A.T.A.B., and E.M.G.; synthesis and characterization, M.S.A.G.H., E.H.E., A.T.A.B., and E.M.G.; in vivo, in silico, bioinformatics experiments and flow cytometric analyses discussion, M.S.N.; writing original manuscript, A.T.A.B., M.S.N., and A.B.; revision and editing, A.T.A.B., M.S.N., and A.B. All authors have read and agree to the published version of the manuscript.

Funding

Researchers Supporting Project, King Saud University.

Acknowledgments

The authors would like to extend their sincere appreciation to the Researchers Supporting Project (RSP-2019/64), King Saud University, Riyadh, Saudi Arabia.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ovaa, H.; Kuijl, C.; Neefjes, J. Recent and new targets for small molecule anti-cancer agents. Drug Discov. Today Technol. 2009, 6, e3–e11. [Google Scholar] [CrossRef] [PubMed]
  2. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Kiss, R.; Sayeski, P.P.; Keserű, G.M. Recent developments on JAK2 inhibitors: A patent review. Expert Opin. Ther. Patents 2010, 20, 471–495. [Google Scholar] [CrossRef] [PubMed]
  4. Verma, A.; Kambhampati, S.; Parmar, S.; Platanias, L.C. Jak family of kinases in cancer. Cancer Metastasis Rev. 2003, 22, 423–434. [Google Scholar] [CrossRef] [PubMed]
  5. Dinakaran, V.S.; Bomma, B.; Srinivasan, K.K. Fused pyrimidines: The heterocycle of diverse biological and pharmacological significance. Der Pharma Chem. 2012, 4, 255–265. [Google Scholar]
  6. Mavrova, A.T.; Dimov, S.; Yancheva, D.; Rangelov, M.; Wesselinova, D.; Tsenov, J.A. Synthesis, anticancer activity and photostability of novel 3-ethyl-2-mercapto-thieno[2,3- d ]pyrimidin-4( 3H )-ones. Eur. J. Med. Chem. 2016, 123, 69–79. [Google Scholar] [CrossRef]
  7. Rheault, T.R.; Caferro, T.R.; Dickerson, S.H.; Donaldson, K.H.; Gaul, M.D.; Goetz, A.S.; Mullin, R.J.; McDonald, O.B.; Petrov, K.G.; Rusnak, D.W.; et al. Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 817–820. [Google Scholar] [CrossRef]
  8. Bánhegyi, P.; Kéri, G.; Örfi, L.; Szekélyhidi, Z.; Wáczek, F. Vichem Chemie Kutato Kft, Tricyclic benzo [4, 5] thieno-[2, 3-d] pyrimidine-4-yl-amin Derivatives, Their Salts, Process for Producing the Compounds and Their Pharmaceutical Use. U.S. Patent 8,802,849, 12 August 2014. [Google Scholar]
  9. Wu, C.-H.; Coumar, M.S.; Chu, C.-Y.; Lin, W.-H.; Chen, Y.-R.; Chen, C.-T.; Shiao, H.-Y.; Rafi, S.; Wang, S.-Y.; Hsu, H.; et al. Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold Based Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain Chirality and Michael Acceptor Group for Maximal Potency. J. Med. Chem. 2010, 53, 7316–7326. [Google Scholar] [CrossRef]
  10. Li, H.; Chen, C.; Xu, S.; Cao, X. Synthesis and Bioevaluation of Thieno[2,3-d]pyrimidinone Derivatives as Potential Tumor Cell Growth Inhibitors. J. Chem. 2013, 2013, 1–6. [Google Scholar] [CrossRef] [Green Version]
  11. Abbas, S.E.; Gawad, N.M.A.; George, R.F.; Akar, Y.A. Synthesis, antitumor and antibacterial activities of some novel tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives. Eur. J. Med. Chem. 2013, 65, 195–204. [Google Scholar] [CrossRef]
  12. Dai, Y.; Guo, Y.; Frey, R.R.; Ji, Z.; Curtin, M.L.; Ahmed, A.A.; Albert, D.H.; Arnold, L.; Arries, S.S.; Barlozzari, T.; et al. Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors. J. Med. Chem. 2005, 48, 6066–6083. [Google Scholar] [CrossRef] [PubMed]
  13. Noronha, G.; Mak, C.C.; Cao, J.; Chow, C.; Daneprovskaia, E.; Renick, J. Anilinopyrimidines as Jak Kinase Inhibitors. Patent WO2009046416A1, 9 April 2009. [Google Scholar]
  14. Zhang, W.; Ma, T.; Li, S.; Yang, Y.; Guo, J.; Kong, L.; Kong, L. Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules. Eur. J. Med. Chem. 2017, 125, 538–550. [Google Scholar] [CrossRef]
  15. Chen, H.; Yang, Z.; Ding, C.; Xiong, A.; Wild, C.; Wang, L.; Ye, N.; Cai, G.; Flores, R.M.; Ding, Y.; et al. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). Eur. J. Med. Chem. 2014, 82, 195–203. [Google Scholar] [CrossRef] [Green Version]
  16. Abdelrahman, S.; El-Gohary, N.S.; Elbendary, E.; El-Ashry, S.M.; Shaaban, M.I. Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of cyclopenta(hepta)[ b ]thiophene and fused cyclohepta[ b ]thiophene analogs. Eur. J. Med. Chem. 2017, 140, 200–211. [Google Scholar] [CrossRef] [PubMed]
  17. Ismail, M.M.; Kamel, M.M.; Mohamed, L.W.; Faggal, S.I.; Galal, M.A. Synthesis and Biological Evaluation of Thiophene Derivatives as Acetylcholinesterase Inhibitors. Molecules 2012, 17, 7217–7231. [Google Scholar] [CrossRef] [PubMed]
  18. Scheich, C.; Puetter, V.; Schade, M. Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85C. J. Med. Chem. 2010, 53, 8362–8836. [Google Scholar] [CrossRef]
  19. Bassetto, M.; Leyssen, P.; Neyts, J.; Yerukhimovich, M.M.; Frick, D.N.; Brancale, A. Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication. Eur. J. Med. Chem. 2016, 123, 31–47. [Google Scholar] [CrossRef]
  20. Rashad, A.; Shamroukh, A.; Abdel-Megeid, R.E.; Mostafa, A.; El-Shesheny, R.; Kandeil, A.; Ali, M.A.; Banert, K. Synthesis and screening of some novel fused thiophene and thienopyrimidine derivatives for anti-avian influenza virus (H5N1) activity. Eur. J. Med. Chem. 2010, 45, 5251–5257. [Google Scholar] [CrossRef]
  21. Deka, S.; Mohan, S.; Saravanan, J.; Kakati, M.; Talukdar, A.; Sahariah, B.; Dey, B.; Sarma, R. Synthesis, characterization and in-vitro antiinflammatory activity of some novel thiophenes. J. Med. Sci. 2012, 5, 159–163. [Google Scholar] [CrossRef]
  22. Kuncha, M.; Shireesha, B.; Naidu, V.G.M.; Ramakrishna, S.; Narsaiah, B.; Rao, A.R.; Diwan, P.V. Anti-inflammatory potential of thienopyridines as possible alternative to NSAIDs. Eur. J. Pharmacol. 2012, 678, 48–54. [Google Scholar] [CrossRef]
  23. Mabkhot, Y.N.; Kheder, N.A.; Barakat, A.; Choudhary, M.I.; Yousuf, S.; Frey, W. Synthesis, Antimicrobial, Anti-Cancer and Molecular Docking of Two Novel Hitherto Unreported Thiophenes. RSC Adv. 2016, 6, 63724–63729. [Google Scholar] [CrossRef]
  24. Dewal, M.B.; Wani, A.S.; Vidaillac, C.; Oupicky, D.; Rybak, M.J.; Firestine, S.M. Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agents. Eur. J. Med. Chem. 2012, 51, 145–153. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Wang, W.; Shangguan, S.; Qiu, N.; Hu, C.; Zhang, L.; Hu, Y. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction, Part 1. Bioorg. Med. Chem. 2013, 21, 2879–2885. [Google Scholar] [CrossRef]
  26. Stephens, C. Synthesis and antiviral/antitumor evaluation of 2-amino- and 2-carboxamido-3-arylsulfonylthiophenes and related compounds as a new class of diarylsulfones. Bioorg. Med. Chem. 2001, 9, 1123–1132. [Google Scholar] [CrossRef]
  27. Titchenell, P.M.; Showalter, H.D.H.; Pons, J.-F.; Barber, A.J.; Jin, Y.; Antonetti, D.A. Synthesis and structure-activity relationships of 2-amino-3-carboxy-4-phenylthiophenes as novel atypical protein kinase C inhibitors. Bioorg. Med. Chem. Lett. 2013, 23, 3034–3038. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Perspicace, E.; Jouan-Hureaux, V.; Ragno, R.; Ballante, F.; Sartini, S.; La Motta, C.; Da Settimo, F.; Chen, B.; Kirsch, G.; Schneider, S.; et al. Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). Eur. J. Med. Chem. 2013, 63, 765–781. [Google Scholar] [CrossRef]
  29. Kassab, A.E.; Gedawy, E.M. ChemInform Abstract: Synthesis and Anticancer Activity of Novel 2-Pyridyl Hexahydrocyclooctathieno[2,3-d]pyrimidine Derivatives. ChemInform 2013, 44, 224–230. [Google Scholar] [CrossRef]
  30. Kattan, S.W.; Nafie, M.S.; Elmgeed, G.A.; Alelwani, W.; Badar, M.; Tantawy, M.A. Molecular docking, anti-proliferative activity and induction of apoptosis in human liver cancer cells treated with androstane derivatives: Implication of PI3K/AKT/mTOR pathway. J. Steroid. Biochem. 2020, 198, 105604. [Google Scholar] [CrossRef]
  31. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3–25. [Google Scholar] [CrossRef]
  32. Lipinski, C. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 2004, 1, 337–341. [Google Scholar] [CrossRef]
  33. Leeson, P.D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 2007, 6, 881–890. [Google Scholar] [CrossRef] [PubMed]
  34. Clark, D.E.; Pickett, S.D. Computational methods for the prediction of ‘drug-likeness’. Drug Discov. Today 2000, 5, 49–58. [Google Scholar] [CrossRef]
  35. Ghose, A.K.; Herbertz, T.; Hudkins, R.L.; Dorsey, B.D.; Mallamo, J.P. Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery. ACS Chem. Neurosci. 2011, 3, 50–68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Veber, D.F.; Johnson, S.R.; Cheng, H.-Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 2002, 45, 2615–2623. [Google Scholar] [CrossRef] [PubMed]
  37. Youssef, E.; El-Moneim, M.A.; Fathalla, W.; Nafie, M.S. Design, synthesis and antiproliferative activity of new amine, amino acid and dipeptide-coupled benzamides as potential sigma-1 receptor. J. Iran. Chem. Soc. 2020, 1–18. [Google Scholar] [CrossRef]
  38. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63. [Google Scholar] [CrossRef]
  39. Nafie, M.S.; Arafa, K.; Sedky, N.K.; Alakhdar, A.A.; Arafa, R.K. Triaryl dicationic DNA minor-groove binders with antioxidant activity display cytotoxicity and induce apoptosis in breast cancer. Interact Biol. Chem. 2020, 324, 109087. [Google Scholar] [CrossRef]
  40. Nafie, M.S.; Tantawy, M.A.; Elmgeed, G.A. Screening of different drug design tools to predict the mode of action of steroidal derivatives as anti-cancer agents. Steroids 2019, 152, 108485. [Google Scholar] [CrossRef]
  41. Salem, M.G.; Aziz, Y.M.A.; Elewa, M.; Elshihawy, H.A.; Said, M.M. Synthesis and molecular modeling of novel non-sulfonylureas as hypoglycemic agents and selective ALR2 inhibitors. Bioorg. Med. Chem. 2019, 27, 3383–3389. [Google Scholar] [CrossRef]
  42. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [Google Scholar] [CrossRef] [Green Version]
Sample Availability: Samples of the compounds 1–35 are available from the authors.
Molecules 25 02523 g001 550
Figure 1. Biologically active compounds based on benzo[b]-thiophene and cycloalkyl[b]thiophene and pharmacophoric/functional groups relationship.
Figure 1. Biologically active compounds based on benzo[b]-thiophene and cycloalkyl[b]thiophene and pharmacophoric/functional groups relationship.
Molecules 25 02523 g001
Molecules 25 02523 sch001 550
Scheme 1. Multicomponent synthesis of 1 and its reaction with isothiocyanates.
Scheme 1. Multicomponent synthesis of 1 and its reaction with isothiocyanates.
Molecules 25 02523 sch001
Molecules 25 02523 sch002 550
Scheme 2. Synthesis of 4–7 starting from compound 1.
Scheme 2. Synthesis of 4–7 starting from compound 1.
Molecules 25 02523 sch002
Molecules 25 02523 sch003 550
Scheme 3. Alkylation of pyrimidinone 8 with different alkylating agents.
Scheme 3. Alkylation of pyrimidinone 8 with different alkylating agents.
Molecules 25 02523 sch003
Molecules 25 02523 sch004 550
Scheme 4. Formation of hydrazones, thiosemicarbazide, and linking new 1,2,4-triazole nucleus to the system via methylene spacer 19.
Scheme 4. Formation of hydrazones, thiosemicarbazide, and linking new 1,2,4-triazole nucleus to the system via methylene spacer 19.
Molecules 25 02523 sch004
Molecules 25 02523 sch005 550
Scheme 5. Synthesis and condensation of the hydrazino derivative 21.
Scheme 5. Synthesis and condensation of the hydrazino derivative 21.
Molecules 25 02523 sch005
Molecules 25 02523 sch006 550
Scheme 6. Cyclization of the hydrazino derivative 21.
Scheme 6. Cyclization of the hydrazino derivative 21.
Molecules 25 02523 sch006
Molecules 25 02523 sch007 550
Scheme 7. Synthesis of compounds 29–35 from the chloro derivative 20.
Scheme 7. Synthesis of compounds 29–35 from the chloro derivative 20.
Molecules 25 02523 sch007
Molecules 25 02523 g002 550
Figure 2. Induction of apoptosis in MCF-7 cells by compound 4 (23.2 μM, 48 h). Cytograms showing annexin-V/propidium iodide stained MCF-7 cells: (A) MCF-7 cells nontreated with the negative control and treated with compound 4; (B) bar chart representation of the apoptosis analysis results, quadrant charts show Q2-1 (necrotic cells, AV–/PI+), Q2-2 (late apoptotic cells, AV+/PI+), Q2-3 (normal cells, AV–/PI–), Q2-4 (early apoptotic cells, AV+/PI–). * p < 0.05 unpaired t-test compared to negative control.
Figure 2. Induction of apoptosis in MCF-7 cells by compound 4 (23.2 μM, 48 h). Cytograms showing annexin-V/propidium iodide stained MCF-7 cells: (A) MCF-7 cells nontreated with the negative control and treated with compound 4; (B) bar chart representation of the apoptosis analysis results, quadrant charts show Q2-1 (necrotic cells, AV–/PI+), Q2-2 (late apoptotic cells, AV+/PI+), Q2-3 (normal cells, AV–/PI–), Q2-4 (early apoptotic cells, AV+/PI–). * p < 0.05 unpaired t-test compared to negative control.
Molecules 25 02523 g002
Molecules 25 02523 g003 550
Figure 3. Cytogram reflecting the cell cycle distribution of MCF-7 cells (A): MCF-7 cells untreated and treated with compound 4 (23.2 μM, 48 h); (B) bar chart representation of the percentage of cell population in different MCF-7 cell cycle phases. * p < 0.05 unpaired t-test compared to negative control.
Figure 3. Cytogram reflecting the cell cycle distribution of MCF-7 cells (A): MCF-7 cells untreated and treated with compound 4 (23.2 μM, 48 h); (B) bar chart representation of the percentage of cell population in different MCF-7 cell cycle phases. * p < 0.05 unpaired t-test compared to negative control.
Molecules 25 02523 g003
Molecules 25 02523 g004 550
Figure 4. Autophagic cell death assessment in MCF-7 treated with compound 4 (IC50 = 23.2 μM) using the acridine orange lysosomal stain coupled with the flow cytometric analysis. The green curve for the negative control (untreated), and the red one for the compound 4-treated cells.
Figure 4. Autophagic cell death assessment in MCF-7 treated with compound 4 (IC50 = 23.2 μM) using the acridine orange lysosomal stain coupled with the flow cytometric analysis. The green curve for the negative control (untreated), and the red one for the compound 4-treated cells.
Molecules 25 02523 g004
Molecules 25 02523 g005 550
Figure 5. Plotting of Drug-likeness score of compound 4 using MolSoft. Non-drug like behavior (green-colored curve) and drug-like behavior (blue-colored curve). Compounds with zero or negative value should not seem to be as drug. Compound 4 has a value of 0.48 (positive value) as a drug-likeness score. It should be regarded as drug-like.
Figure 5. Plotting of Drug-likeness score of compound 4 using MolSoft. Non-drug like behavior (green-colored curve) and drug-like behavior (blue-colored curve). Compounds with zero or negative value should not seem to be as drug. Compound 4 has a value of 0.48 (positive value) as a drug-likeness score. It should be regarded as drug-like.
Molecules 25 02523 g005
Molecules 25 02523 g006 550
Figure 6. Solid Ehrlich Carcinoma (SEC)-bearing mice model. Different solid tumor mass, volume, tumor inhibition ratio (TIR %) values are attributed to the antitumor activity. Mean ± SEM values of mice in each group (n = 8). * Mean ± SEM values with a significant difference in tumor volume and tumor weight values compared to the SEC control using an unpaired t-test (p ≤ 0.05) using GraphPad prism.
Figure 6. Solid Ehrlich Carcinoma (SEC)-bearing mice model. Different solid tumor mass, volume, tumor inhibition ratio (TIR %) values are attributed to the antitumor activity. Mean ± SEM values of mice in each group (n = 8). * Mean ± SEM values with a significant difference in tumor volume and tumor weight values compared to the SEC control using an unpaired t-test (p ≤ 0.05) using GraphPad prism.
Molecules 25 02523 g006
Molecules 25 02523 g007 550
Figure 7. Summarized methodology of Solid Ehrlich Carcinoma (SEC)-bearing mice in vivo.
Figure 7. Summarized methodology of Solid Ehrlich Carcinoma (SEC)-bearing mice in vivo.
Molecules 25 02523 g007
Table
Table 1. The in vitro inhibition % found using (100 µg/mL) of a single dose and IC50 in µg/mL and µM of the tested compounds on MCF-7 and HepG-2 cell lines.
Table 1. The in vitro inhibition % found using (100 µg/mL) of a single dose and IC50 in µg/mL and µM of the tested compounds on MCF-7 and HepG-2 cell lines.
EntryMCF-7 HepG-2
Inhibition %IC50
µg/mL		IC50
µM		Inhibition %IC50
µg/mL		IC50
µM
227.12551NDND42.85714NDND
346.93572NDND43.42105NDND
480.625723.278.6363611.738.8
575.9191219.352.976.4122119.352.9
638.56502NDND45.17544NDND
774.7794148131.373.5877937101.2
849.0284NDND52.41228NDND
945.06726NDND81.7982536.5140.7
1067.70833NDND78.1818226.589.4
1145.29148NDND72.9824616.550.9
1238.93871NDND73.070183187.5
1356.65172NDND66.2280727.594.0
1461.1360243154.569.3421133.6120.7
1560.463382253.273.245612253.2
1666.66667NDND77.090912568.2
1767.70833NDND79.0909142110.4
1968.41912NDND77.1755738.5334.42
2034.90284NDND34.21053NDND
2160.3886428127.169.7368413.661.7
2231.98381NDND30.61224NDND
231.00005NDND3.508772NDND
2472.395831340.378.636361031.0
2538.7145NDND29.82456NDND
2670.6770816.471.277.2727329125.9
2779.062521.776.377.7272732.6114.6
2870.4035915.559.147.36842NDND
2980.208331149.976.3636414.565.8
3072.916677.431.678.727278.837.6
3176.041679.833.280.454551757.5
3247.36842NDND51.83673NDND
3371.87531.295.981.3636440122.9
3457.8125NDND77.63636NDND
ND: Not determined.
Table
Table 2. Analysis of ligand-receptor interactions with binding energies of docked compound 4 inside three proteins 3ZMM, 4C62, and 5AEP as Jak2 inhibitors.
Table 2. Analysis of ligand-receptor interactions with binding energies of docked compound 4 inside three proteins 3ZMM, 4C62, and 5AEP as Jak2 inhibitors.
Protein
(PDB Code)		Binding Affinity
(Kcal/mol)		Type of InteractionBond Length (Aº)Interaction Moiety InvolvedAmino Acid
3ZMM–14.32H-acceptor1.97C=OLeu 932
Molecules 25 02523 i001
4C62–13.39H-acceptor1.84C=OLeu 932
Molecules 25 02523 i002
5AEP–11.38H-acceptor1.67C=OLeu 932
Molecules 25 02523 i003
Superimposed compound 4 (orange), and the co-crystalized ligand (green) of the three studied 3ZMM, 4C62, and 5AEP proteins.
Table
Table 3. In silico ADME pharmacokinetics properties.
Table 3. In silico ADME pharmacokinetics properties.
#Molinspiration 2018.10MolSoft
MWt
(D)		MV (A3)PSA (A2)Log PnrotbnviolationsHBAHBDSolubility
(mg/L)		Drug-Likeness Score
4301.79254.1855.402.825041187.990.48
31295.40267.1737.814.8020312.510.48
24322.43290.4350.174.3330412.130.73
30234.31209.1535.023.03204014.580.15
“Mwt: Molecular Weight, MV: Molecular Volume, PAS: Polar Surface Area, Log P: Octanol-water partition coefficient, nrotb: number of rotatable bond, nviolations: number of violations, HBA: Hydrogen Bond Acceptor, HBD: Hydrogen Bond Donor” [37].
Table
Table 4. Evaluation of liver enzymes and hematological parameters in the studied groups.
Table 4. Evaluation of liver enzymes and hematological parameters in the studied groups.
TreatmentsPositive ControlSEC ControlSEC + Comp 4SEC + 5-FU
ALT *# (I/U)43.53 ± 1.0684.65 ± 2.164.28 ± 1.6451.31 ± 1.41
AST *# (I/U)45.75 ± 0.9797.64 ± 1.7559.89 ± 1.8550.64 ± 0.97
Hb *# (g/dL)7.9 ± 0.863.99 ± 0.215.99 ± 0.497.02 ± 0.83
RBCs count *# (× 106/μL)5.14 ± 0.653.28 ± 0.734.43 ± 0.474.98 ± 021
WBCs count *# (× 103/μL)3.69 ± 0.534.89 ± 0.494.21 ± 0.433.98 ± 0.32
* Mean ± SEM values of mice in each group (n = 8). # Values are significantly different (p ≤ 0.05), un-paired test using GraphPad prism.

Share and Cite

MDPI and ACS Style

Gad, E.M.; Nafie, M.S.; Eltamany, E.H.; Hammad, M.S.A.G.; Barakat, A.; Boraei, A.T.A. Discovery of New Apoptosis-Inducing Agents for Breast Cancer Based on Ethyl 2-Amino-4,5,6,7-Tetra Hydrobenzo[b]Thiophene-3-Carboxylate: Synthesis, In Vitro, and In Vivo Activity Evaluation. Molecules 2020, 25, 2523. https://doi.org/10.3390/molecules25112523

AMA Style

Gad EM, Nafie MS, Eltamany EH, Hammad MSAG, Barakat A, Boraei ATA. Discovery of New Apoptosis-Inducing Agents for Breast Cancer Based on Ethyl 2-Amino-4,5,6,7-Tetra Hydrobenzo[b]Thiophene-3-Carboxylate: Synthesis, In Vitro, and In Vivo Activity Evaluation. Molecules. 2020; 25(11):2523. https://doi.org/10.3390/molecules25112523

Chicago/Turabian Style

Gad, Emad M., Mohamed S. Nafie, Elsayed H. Eltamany, Magdy S. A. G. Hammad, Assem Barakat, and Ahmed T. A. Boraei. 2020. "Discovery of New Apoptosis-Inducing Agents for Breast Cancer Based on Ethyl 2-Amino-4,5,6,7-Tetra Hydrobenzo[b]Thiophene-3-Carboxylate: Synthesis, In Vitro, and In Vivo Activity Evaluation" Molecules 25, no. 11: 2523. https://doi.org/10.3390/molecules25112523

APA Style

Gad, E. M., Nafie, M. S., Eltamany, E. H., Hammad, M. S. A. G., Barakat, A., & Boraei, A. T. A. (2020). Discovery of New Apoptosis-Inducing Agents for Breast Cancer Based on Ethyl 2-Amino-4,5,6,7-Tetra Hydrobenzo[b]Thiophene-3-Carboxylate: Synthesis, In Vitro, and In Vivo Activity Evaluation. Molecules, 25(11), 2523. https://doi.org/10.3390/molecules25112523

Article Metrics

Back to TopTop